

Data Sharing Statement

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. DOI: 10.1056/NEJMoa2035389.

Question	Authors' Response
Will the data collected for your study be made available to others?	No
Would you like to offer context for your decision?	The results of this study are preliminary and the study is ongoing. Access to patient-level data and supporting clinical documents with qualified external researchers may be available upon request once the trial is complete.
Which data?	—
Additional information about data	—
How or where can the data be obtained?	—
When will data availability begin?	—
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on December 30, 2020, at NEJM.org.